| scholarly article | Q13442814 |
| P50 | author | Agnieszka Latosińska | Q56957190 |
| Maria Frantzi | Q61793606 | ||
| P2093 | author name string | Axel S Merseburger | |
| Harald Mischak | |||
| P2860 | cites work | iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer | Q21134794 |
| In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine | Q24337415 | ||
| Back to the future in bladder cancer research. | Q51700873 | ||
| Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer. | Q52936872 | ||
| Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. | Q53596875 | ||
| STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement | Q56525359 | ||
| Clinical Proteomics: Closing the Gap from Discovery to Implementation | Q57711756 | ||
| Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics | Q57712052 | ||
| Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration | Q59822429 | ||
| Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study | Q61758647 | ||
| Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis | Q83171676 | ||
| Proteomics biomarkers for solid tumors: Current status and future prospects | Q89061368 | ||
| Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. | Q50708333 | ||
| Metabolomic signatures of aggressive prostate cancer. | Q50860265 | ||
| Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. | Q51068972 | ||
| Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation. | Q51467458 | ||
| Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer | Q24658328 | ||
| Advances in mass spectrometry-based clinical biomarker discovery | Q26770004 | ||
| PSA and beyond: alternative prostate cancer biomarkers | Q26770646 | ||
| Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). | Q27852197 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Advances in targeted proteomics and applications to biomedical research | Q28066912 | ||
| Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression | Q28286300 | ||
| An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis | Q28533442 | ||
| Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease | Q28534235 | ||
| Discovery and validation of urinary biomarkers for prostate cancer | Q30438582 | ||
| Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer | Q33326784 | ||
| Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease | Q33449075 | ||
| Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. | Q33515339 | ||
| Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population | Q33572829 | ||
| Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. | Q33609420 | ||
| Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes | Q33611314 | ||
| A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. | Q33642692 | ||
| Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer | Q33644807 | ||
| A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness | Q33839248 | ||
| Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. | Q33850638 | ||
| Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay | Q34093537 | ||
| Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker | Q34276511 | ||
| Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment | Q34475350 | ||
| Identification, prioritization, and evaluation of glycoproteins for aggressive prostate cancer using quantitative glycoproteomics and antibody-based assays on tissue specimens | Q34533360 | ||
| Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer | Q34602348 | ||
| MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. | Q34954041 | ||
| Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer | Q35082335 | ||
| MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer. | Q35602182 | ||
| Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. | Q35678391 | ||
| Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort | Q35832300 | ||
| Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Q35956276 | ||
| A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy | Q40363294 | ||
| Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. | Q40368993 | ||
| Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer | Q40395168 | ||
| High molecular mass proteome of androgen-independent prostate cancer. | Q40458153 | ||
| Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. | Q40471358 | ||
| Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. | Q40707371 | ||
| Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. | Q40828142 | ||
| Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application | Q41173805 | ||
| Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study. | Q41851428 | ||
| Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer | Q42067159 | ||
| Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. | Q42151262 | ||
| Metabolomics and its Application to the Development of Clinical Laboratory Tests for Prostate Cancer | Q42378320 | ||
| Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy | Q43093212 | ||
| Discovery and validation of urinary biomarkers for detection of renal cell carcinoma | Q44638298 | ||
| Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort | Q44902653 | ||
| Recommendations for biomarker identification and qualification in clinical proteomics | Q45200767 | ||
| Technical considerations for large-scale parallel reaction monitoring analysis | Q45789427 | ||
| A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease | Q46047736 | ||
| Genomic Markers in Prostate Cancer Decision Making | Q46563546 | ||
| A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. | Q46658469 | ||
| Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide | Q47213748 | ||
| Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results | Q47568399 | ||
| Clinical Proteomics for Precision Medicine: The Bladder Cancer Case | Q47694209 | ||
| Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy | Q48355294 | ||
| The molecular make-up of a tumour: proteomics in cancer research | Q36098149 | ||
| Implementation of proteomic biomarkers: making it work | Q36297774 | ||
| Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer | Q36298306 | ||
| A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. | Q36326056 | ||
| Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease | Q36327993 | ||
| Quality assessment for clinical proteomics | Q36698467 | ||
| Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design | Q36936929 | ||
| Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy | Q36945088 | ||
| Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer | Q37550588 | ||
| Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer. | Q37648510 | ||
| Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development | Q37714579 | ||
| Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. | Q37922910 | ||
| Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study | Q38045642 | ||
| Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience | Q38049916 | ||
| Antibody-based proteomics and biomarker research - current status and limitations | Q38187396 | ||
| Seminal plasma as a diagnostic fluid for male reproductive system disorders | Q38202841 | ||
| A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer | Q38281341 | ||
| Identification of prostate cancer biomarkers in urinary exosomes | Q38286457 | ||
| Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker | Q38378261 | ||
| Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies | Q38392009 | ||
| Stable isotope labelling methods in mass spectrometry-based quantitative proteomics | Q38468333 | ||
| Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy | Q38502644 | ||
| Developing proteomic biomarkers for bladder cancer: towards clinical application | Q38511509 | ||
| SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine | Q38608455 | ||
| Extracellular Vesicles and Their Role in Urologic Malignancies | Q38754260 | ||
| The Proteome of Primary Prostate Cancer | Q38933701 | ||
| EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent | Q38939206 | ||
| Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer | Q39116735 | ||
| Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer | Q39545306 | ||
| Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. | Q39796352 | ||
| Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers | Q39851064 | ||
| Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. | Q39859123 | ||
| 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. | Q39866694 | ||
| Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany | Q40008598 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P577 | publication date | 2018-08-29 | |
| P1433 | published in | Diagnostics | Q27726498 |
| P1476 | title | Promise and Implementation of Proteomic Prostate Cancer Biomarkers | |
| P478 | volume | 8 |
| Q92410904 | The Tumor Microenvironments of Lethal Prostate Cancer | cites work | P2860 |
Search more.